Compare Occidental Petroleum Corporation (OXY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Occidental Petroleum Corporation trades at $61.79 (market cap $61.39B), while Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B). The key difference: Occidental Petroleum Corporation is far larger — about 8.4× Spyre Therapeutics Inc. Common Stock's market cap, and Occidental Petroleum Corporation pays a 1.82% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Occidental Petroleum Corporation for 92 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| OXY | SYRE | |
|---|---|---|
Market Cap | $61.39B | $7.35B |
Volume | 8,708,264 | 1,624,631 |
Sector | Energy | Health |
52-Week High | $66.24 | $108.92 |
52-Week Low | $38.92 | $22.18 |
Typical Hold Time | 92 Days | 0 Days |
Enterprise Value | $80.15B | $6.35B |
Dividend Yield | 1.82% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
